PolyethyleneGlycol3350 Laxative vs Placebo in Constipated Children
This study has been completed.
Sponsor:
Braintree Laboratories
Information provided by:
Braintree Laboratories
ClinicalTrials.gov Identifier:
NCT00153114
First received: September 7, 2005
Last updated: February 6, 2013
Last verified: February 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Assess the safety and efficacy of polyethyleneglycol3350 laxative as compared to placebo therapy in pediatric patients with a history of constipation.
| Condition | Intervention | Phase |
|---|---|---|
|
Constipation |
Drug: polyethyleneglycol3350 |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment |
| Official Title: | PolyethyleneGlycol3350 Laxative vs Placebo in Constipated Children |
Resource links provided by NLM:
MedlinePlus related topics:
Constipation
Drug Information available for:
Polyethylene glycol
U.S. FDA Resources
Further study details as provided by Braintree Laboratories:
Primary Outcome Measures:
- Greater than 2 bowel movements per week
Secondary Outcome Measures:
- Analysis of individual ROME I criteria
- Safety (adverse event and laboratory testing)
| Estimated Enrollment: | 100 |
| Study Start Date: | January 2003 |
| Primary Completion Date: | September 2004 (Final data collection date for primary outcome measure) |
Eligibility| Ages Eligible for Study: | 4 Years to 16 Years |
| Genders Eligible for Study: | Both |
Criteria
Inclusion Criteria:
- Male or female outpatients between the ages of 4 to 16 years.
- Adolescent female patients must not be pregnant or lactating.
- constipated according to ROME I definition
- Two or fewer bowel movements during the initial observation week.
- Absence of a stool impaction
- Bowel movement after receiving enema
- Are otherwise in good health, as judged by a physical examination.
- Parent or guardian is mentally competent to sign an instrument of informed consent
Exclusion Criteria:
- Patients with heme positive stool at baseline exam.
- Patients with fecal impaction at baseline, or after the observation period, as indicated by physical exam
- Patients with known or suspected perforation or obstruction other than fecal impaction.
- Patients who are breastfeeding, pregnant or intend to become pregnant during the study.
- Female patients of childbearing potential who refuse a pregnancy test.
- Patients with a known history of organic cause for their constipation.
- Patients with congenital malformations that produce constipation (Hirschsprung's disease, imperforate anus, children with cerebral palsy or other neurologic abnormalities, or systemic diseases).
- History of gastric retention, inflammatory bowel disease, bowel resection, or colostomy.
- Use of concomitant medications that cause constipation
- Patients who, in the opinion of the investigator, should not be included in the study for any reason, including inability to follow study procedures.
- Patients with known allergy to polyethyleneglycol or polyethyleneglycol containing medications.
- Patients with clinically significant elevations of TSH or abnormal plasma electrolytes.
- Patients who, within the past 30 days have participated in an investigational clinical study
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00153114
Locations
| United States, Massachusetts | |
| Boston, Massachusetts, United States, 02115 | |
| United States, New Jersey | |
| Morristown, New Jersey, United States, 07962 | |
| United States, Pennsylvania | |
| Pittsburgh, Pennsylvania, United States, 15213 | |
Sponsors and Collaborators
Braintree Laboratories
Investigators
| Principal Investigator: | Samuel Nurko, MD | Children's Hospital Boston |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00153114 History of Changes |
| Other Study ID Numbers: | 851-15 |
| Study First Received: | September 7, 2005 |
| Last Updated: | February 6, 2013 |
| Health Authority: | United States: Food and Drug Administration |
Additional relevant MeSH terms:
|
Constipation Signs and Symptoms, Digestive Signs and Symptoms Laxatives |
Gastrointestinal Agents Therapeutic Uses Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 21, 2013